TWI628180B - 作為ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物 - Google Patents

作為ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物 Download PDF

Info

Publication number
TWI628180B
TWI628180B TW104119646A TW104119646A TWI628180B TW I628180 B TWI628180 B TW I628180B TW 104119646 A TW104119646 A TW 104119646A TW 104119646 A TW104119646 A TW 104119646A TW I628180 B TWI628180 B TW I628180B
Authority
TW
Taiwan
Prior art keywords
compound
alkyl
reaction
acid
pyrido
Prior art date
Application number
TW104119646A
Other languages
English (en)
Chinese (zh)
Other versions
TW201625612A (zh
Inventor
吳成德
Chengde Wu
于濤
Tao Yu
陳曙輝
Shuhui Chen
Original Assignee
正大天晴藥業集團股份有限公司
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54934872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI628180(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed by 正大天晴藥業集團股份有限公司, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. filed Critical 正大天晴藥業集團股份有限公司
Publication of TW201625612A publication Critical patent/TW201625612A/zh
Application granted granted Critical
Publication of TWI628180B publication Critical patent/TWI628180B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
TW104119646A 2014-06-17 2015-06-17 作為ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物 TWI628180B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN201410271282.9 2014-06-17
CN201510324348 2015-06-12
CN201510324348.0 2015-06-12

Publications (2)

Publication Number Publication Date
TW201625612A TW201625612A (zh) 2016-07-16
TWI628180B true TWI628180B (zh) 2018-07-01

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104119646A TWI628180B (zh) 2014-06-17 2015-06-17 作為ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物

Country Status (11)

Country Link
US (1) US9856256B2 (enExample)
EP (1) EP3159341B8 (enExample)
JP (1) JP6680774B2 (enExample)
KR (1) KR102495840B1 (enExample)
CN (1) CN106470992B (enExample)
AU (1) AU2015276699B2 (enExample)
CA (1) CA2951971C (enExample)
EA (1) EA032642B1 (enExample)
ES (1) ES2754264T3 (enExample)
TW (1) TWI628180B (enExample)
WO (1) WO2015192760A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017101847A1 (zh) * 2015-12-16 2017-06-22 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN113316575B (zh) * 2019-01-24 2022-03-18 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
BR112022010561A2 (pt) 2019-12-02 2022-11-16 Storm Therapeutics Ltd Compostos poli-heterocíclicos como inibidores de mettl3
US20230132982A1 (en) * 2020-02-10 2023-05-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
US20230119759A1 (en) 2020-03-10 2023-04-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
EP4197539A4 (en) * 2020-09-15 2024-09-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
WO2022121929A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010192A1 (en) * 2010-07-02 2012-01-12 Gilead Sciences, Inc. Fused Heterocyclic Compounds as Ion Channel Modulators
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TW201602107A (zh) * 2014-06-17 2016-01-16 南京明德新藥研發股份有限公司 作為ｍＴＯＲ／ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709473B2 (en) * 2003-10-10 2010-05-04 Pfizer Inc. Substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors
JP5642963B2 (ja) * 2006-06-30 2014-12-17 スネシス ファーマシューティカルズ，インコーポレイティド ピリジノニルｐｄｋ１阻害剤
EP2211615A4 (en) * 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
AU2009260447B2 (en) * 2008-05-30 2012-03-29 Amgen Inc. Inhibitors of PI3 kinase
US9284315B2 (en) * 2011-11-17 2016-03-15 Zuanzhu Pharma Co., Ltd. Three-ring PI3K and/or mTOR inhibitor
CN103539777B (zh) * 2012-07-13 2016-03-02 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010192A1 (en) * 2010-07-02 2012-01-12 Gilead Sciences, Inc. Fused Heterocyclic Compounds as Ion Channel Modulators
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TW201602107A (zh) * 2014-06-17 2016-01-16 南京明德新藥研發股份有限公司 作為ｍＴＯＲ／ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物

Also Published As

Publication number Publication date
CA2951971A1 (en) 2015-12-23
EA201790016A1 (ru) 2017-06-30
EP3159341B8 (en) 2020-01-08
JP2017519821A (ja) 2017-07-20
KR20170016465A (ko) 2017-02-13
US9856256B2 (en) 2018-01-02
US20170137420A1 (en) 2017-05-18
CA2951971C (en) 2024-09-10
EP3159341A1 (en) 2017-04-26
EA032642B1 (ru) 2019-06-28
EP3159341A4 (en) 2018-05-16
KR102495840B1 (ko) 2023-02-03
ES2754264T3 (es) 2020-04-16
AU2015276699A1 (en) 2017-01-19
CN106470992B (zh) 2018-11-06
EP3159341B1 (en) 2019-08-21
AU2015276699B2 (en) 2019-10-10
TW201625612A (zh) 2016-07-16
WO2015192760A1 (zh) 2015-12-23
JP6680774B2 (ja) 2020-04-15
CN106470992A (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
TWI628180B (zh) 作為ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物
TWI863945B (zh) 2-側氧基喹唑啉衍生物作為甲硫胺酸腺苷基轉移酶２ａ抑制劑
JP6577613B2 (ja) キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
CN105461711B (zh) 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
TWI600655B (zh) 作為ｍＴＯＲ／ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物
TWI546302B (zh) 稠合雜環化合物
TWI694998B (zh) Jak抑制劑
EP3533787B1 (en) Pyridone compound as c-met inhibitor
WO2019134661A1 (zh) 异吲哚啉酮及其衍生物作为csf-1r抑制剂
TW202204351A (zh) 具有大環結構的化合物及其用途
TW202214634A (zh) 雜環化合物及其衍生物
WO2017215588A1 (zh) 作为Akt抑制剂的二氢吡唑氮杂卓类化合物
HK1238629B (zh) 作为pi3k抑制剂的吡啶并[1，2-a]嘧啶酮类似物
TW201808953A (zh) 稠環或三環芳基嘧啶化合物用作激酶抑制劑
CN121159525A (zh) Cdk7抑制剂化合物、药物组合物及其制备方法和应用
HK1238629A1 (en) Pyridino[1,2-a]pyrimidone analogue used as pi3k inhibitor